Epidermolysis bullosa pruriginosa treated with dupilumab
Amanda Zhou, Alicia J. Little, Richard J. Antaya
Abstract
Epidermolysis bullosa pruriginosa (EBP) is a variant of dystrophic epidermolysis bullosa characterized by intense pruritus and prurigo nodularis-like lesions. While medical therapies for EBP exist, current treatments are not consistently effective, and symptoms often cause decreased quality of life. Here, we report two cases of EBP treated with dupilumab, which decreased symptoms of pruritus and improved skin findings. Both patients have been on dupilumab for over one year with sustained improvement and no adverse effects; although in one patient, increased dosing was required to attain optimal control of disease.
Topics & Concepts
DupilumabMedicinePrurigo nodularisDermatologyAdverse effectEpidermolysis bullosaQuality of life (healthcare)Atopic dermatitisInternal medicineNursingSkin and Cellular Biology ResearchAutoimmune Bullous Skin DiseasesDermatology and Skin Diseases